Key points are not available for this paper at this time.
AIMS: To quantify the effect of liraglutide on systolic blood pressure (SBP) and pulse in patients with type 2 diabetes (T2D), and assess the influence of covariates on observed SBP reductions. METHODS: A patient-level pooled analysis of six phase 3, randomized trials was conducted. RESULTS: The analysis included 2792 randomized patients. In the intention-to-treat population (n=2783), mean ±SE SBP reductions from baseline with liraglutide 1.2 mg (2.7 0.8 mmHg) and 1.8 mg (2.9 0.7 mmHg) once daily were significantly greater than with placebo (0.5 0.9 mmHg; P=0.0029 and P=0.0004, respectively) after 26 weeks, and were evident after 2 weeks. Liraglutide was also associated with significantly greater SBP reductions than glimepiride and, at a dose of 1.8 mg, insulin glargine and rosiglitazone. SBP reductions with liraglutide weakly correlated with weight loss (Pearson's correlation coefficient: 0.08-0.12; P≤0.0148). No dependence of these reductions on concomitant antihypertensive medications was detected (P=0.1304). Liraglutide 1.2 and 1.8 mg were associated with mean increases in pulse of 3 beats per minute (bpm), versus a 1 bpm increase with placebo (P<0.0001 for each dose versus placebo). CONCLUSIONS: Liraglutide reduces SBP in patients with T2D, including those receiving concomitant antihypertensive medication.
Fonseca et al. (Tue,) studied this question.